BioStorage Technologies Becomes Green Powered Through Use of 100 Percent Renewable Energy
BioStorage Technologies, a worldwide provider of long- and short-term storage of biomaterials, sample management and cold chain logistics, today announced its full-service biorepository near Frankfurt, Germany received green certification from ENTEGA Vertrieb GmbH & Co., a leading Germany-based sustainable energy supplier.
Serving global pharmaceutical and biotech firms, donor organizations and biobanks as well as research and academic organizations, BioStorage Technologies’ 18,000 square-foot (1,672 square-meter) biorepository, uses an estimated 360,000-kilowatt hours (kWh) of power per year. By using 100 percent renewable energy, BioStorage Technologies is preventing the generation of an estimated 189 tons of environmentally harmful carbon dioxide (CO2) in the first year, thus making a valuable contribution to environmental protection. As the European operation grows, the amount of carbon dioxide prevented from generation will increase significantly.
“We are pleased to have all of our global facilities operating with 100 percent renewable energy,” said F. John Mills, M.D., Ph.D., chairman and chief executive officer at BioStorage Technologies. “This initiative demonstrates our commitment to conserving energy and improving the health of the environment by decreasing carbon dioxide emissions.”
Dr. Wolfgang Höffer, managing director of BioStorage Technologies’ European operations, adds, “Using renewable energy is only one of the green initiatives underway at our facilities. Additional aspects of the initiative include environmentally conscious management of waste disposal, logistics, water consumption and paper use.” BioStorage Technologies is also researching low VOC (Volatile Organic Compound) cleaning agents, the use of fair-trade products where applicable and other ways of making facilities and services better for the overall health of individuals and the environment.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
